Plain-English translation of NCT03829540 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach called — engineered immune cells designed to recognize and attack cancer cells in patients with aggressive CD4+ blood cancers that have not responded to standard treatments. Your own T cells (a type of immune cell) are collected, modified in a laboratory to recognize cancer cells, and then given back to you as an infusion. The goal is to help your immune system fight the cancer more effectively.
Certain blood cancers involving CD4+ T cells are particularly aggressive and often come back or don't respond well to standard chemotherapy. This trial exists because doctors need new treatment options for patients whose cancers have stopped responding to conventional therapy.
You likely qualify if…
You likely don't qualify if…
First, doctors will check whether your cancer and overall health make you eligible. If you qualify, you'll undergo a procedure called leukapheresis to collect your T cells — this takes a few hours and is done at an apheresis center. Your cells are then sent to a laboratory where they are engineered and grown over several weeks. Meanwhile, you'll receive conditioning chemotherapy to prepare your body. Once the engineered cells are ready, you'll return for an infusion that takes about 20 minutes, and then you'll be monitored closely for side effects and response to treatment.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States